Navigation Links
Merck Serono's Safinamide Significantly Improved Motor Function in Patients With Advanced Parkinson's Disease in a Phase III Pivotal Trial
Date:2/3/2009

d Kirschbaum, Merck Serono's Executive Vice President for Global Research and Development. "These results represent a further step toward our goal to provide patients and doctors with urgently needed new treatment possibilities in the Neurodegenerative Diseases therapeutic area."

Dr Ravi Anand, Newron's Chief Medical Officer, said: "These results are extremely encouraging. In addition to increasing "ON" time and reducing total "OFF" time, as well as "OFF" time after morning dose in patients with mid- to late-stage Parkinson's disease receiving optimized treatment with drugs including levodopa, dopamine agonists, COMT inhibitors, anti-cholinergics and amantidine, the results indicate a statistically significant improvement of motor function. Previously reported results from Phase II and Phase III studies have shown improvement of motor symptoms in early Parkinson's disease patients on dopamine agonist monotherapy. These results from both early and advanced Parkinson's disease patients underline safinamide's potential to be used as adjunctive therapy along the continuum of Parkinson's disease."

This Phase III study was a six-month (24-week), randomized, double-blind, placebo-controlled international trial. It enrolled 669 patients with mid- to late-stage idiopathic Parkinson's disease (more than three years of disease duration) receiving stable doses of levodopa, who had motor fluctuations with >1.5 hours of "OFF" time(1) during the day. Additionally, patients may have received concomitant treatment with stable doses of a dopamine agonist and/or an anti-cholinergic drug. After a four-week levodopa dosage stabilization phase, study participants were randomized to one of the three arms of the trial (1:1:1) to receive either one of two different doses of safinamide (50 or 100 mg once daily: 223 and 224 patients, respectively) or matching placebo tablets (222 patients), as adjunctive treatment to their levodopa therap
'/>"/>

SOURCE Merck Serono
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6

Related medicine technology :

1. Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial
2. Merck Serono Announces Initiation of the ORACLE MS Trial to Evaluate Cladribine Tablets in Patients at Risk of Developing Multiple Sclerosis
3. Merck Serono Completes Enrollment in the REFLEX Trial of Rebif(R) in Patients at Risk of Developing Multiple Sclerosis
4. Diakron Licenses Anticoagulant Drug Candidate from Merck & Co., Inc.
5. MicroDose Technologies Announces Achievement of Phase I Clinical Milestone Triggering First Milestone Payment Under Collaboration with Merck & Co., Inc.
6. NicOx Announces Initiation of First Phase 1 Study of Investigational Nitric Oxide-Donating Agent in Hypertensive Patients by Merck & Co., Inc.
7. Iomai and Merck & Co., Inc. Evaluate Use of Iomai Immunostimulant Patch
8. Microbicide Developer Receives License for Novel HIV Microbicide Candidate From Merck & Co., Inc.
9. Parker Waichman Alonso LLP and Affiliated Lawfirms Have Filed a Class Action Lawsuit in the United States District Court for the Eastern District of New York Against Merck & Co., Inc. and Schering-Plough Corporation
10. Ambrx Enters FGF-21 Type 2 Diabetes Drug Discovery Collaboration with Merck and Co. Inc.
11. MJFF and Merck Serono (EMD Serono in North America) Join Forces on $2-Million Initiative to Drive Treatments for PD-Related Cognitive Dysfunction and Mood Disorders
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... Research and Markets has ... Market (Technology, Types, Applications, Services and Geography) - ... their offering. A new report ... - Size, Share, Global Trends, Company Profiles, Demand, ... 2013 - 2020", suggests that the global biosimilars ...
(Date:8/20/2014)... 20, 2014 Research and Markets  has announced ... report to their offering. Global Market ... on Pralmorelin globally and regionally ( Europe , ... , Latin America etc.). It captures ... This report focuses on three primary areas; manufacture methods & ...
(Date:8/20/2014)... , Aug. 20, 2014 Reportlinker.com announces ... in its catalogue: Global Coatings for ... This report analyzes the ... US$ Million by the following Product Segments: Active ... The report provides separate comprehensive analytics for the ...
Breaking Medicine Technology:Global Biosimilars/Follow-on-Biologics Market (Technology, Types, Applications, Services and Geography) - Research Report, 2013 - 2020 2Global Market Report of Pralmorelin 2Global Coatings for Medical Devices Industry 2Global Coatings for Medical Devices Industry 3Global Coatings for Medical Devices Industry 4Global Coatings for Medical Devices Industry 5Global Coatings for Medical Devices Industry 6Global Coatings for Medical Devices Industry 7Global Coatings for Medical Devices Industry 8Global Coatings for Medical Devices Industry 9Global Coatings for Medical Devices Industry 10Global Coatings for Medical Devices Industry 11Global Coatings for Medical Devices Industry 12Global Coatings for Medical Devices Industry 13Global Coatings for Medical Devices Industry 14Global Coatings for Medical Devices Industry 15Global Coatings for Medical Devices Industry 16Global Coatings for Medical Devices Industry 17Global Coatings for Medical Devices Industry 18Global Coatings for Medical Devices Industry 19Global Coatings for Medical Devices Industry 20Global Coatings for Medical Devices Industry 21
... Dec. 29, 2010 Reportlinker.com announces that a ... catalogue: The Market for Pharmaceuticals ... http://www.reportlinker.com/p0203101/The-Market-for-Pharmaceuticals-in-Brazil-Russia-India--China.html Evaluate the ... Brazil, Russia, India and China now and in ...
... Dec. 29, 2010 Centocor Ortho Biotech Inc. announced ... Application (sBLA) with the U.S. Food and Drug Administration ... treatment of moderately to severely active ulcerative colitis (UC) ... to conventional therapy.  REMICADE was designated orphan drug status ...
Cached Medicine Technology:Reportlinker Adds The Market for Pharmaceuticals in Brazil, Russia, India & China 2Reportlinker Adds The Market for Pharmaceuticals in Brazil, Russia, India & China 3Reportlinker Adds The Market for Pharmaceuticals in Brazil, Russia, India & China 4Reportlinker Adds The Market for Pharmaceuticals in Brazil, Russia, India & China 5Centocor Ortho Biotech Inc. Submits Application to FDA Seeking REMICADE® Pediatric Ulcerative Colitis Indication 2Centocor Ortho Biotech Inc. Submits Application to FDA Seeking REMICADE® Pediatric Ulcerative Colitis Indication 3Centocor Ortho Biotech Inc. Submits Application to FDA Seeking REMICADE® Pediatric Ulcerative Colitis Indication 4Centocor Ortho Biotech Inc. Submits Application to FDA Seeking REMICADE® Pediatric Ulcerative Colitis Indication 5Centocor Ortho Biotech Inc. Submits Application to FDA Seeking REMICADE® Pediatric Ulcerative Colitis Indication 6
(Date:8/20/2014)... Gray HealthDay Reporter WEDNESDAY, ... rare, colds, flu and other minor infections might trigger a ... children, a new study suggests. Just five out of ... States, said Dr. Heather Fullerton, lead author of the study ... of California, San Francisco Benioff Children,s Hospital. "It seems infections ...
(Date:8/20/2014)... August 20, 2014 The Board of ... Perkins Eastman is pleased to announce the expansion ... in China and the surrounding region. In ... Richard Sprow AIA has relocated to the firm’s ... in healthcare planning and design and to better support ...
(Date:8/20/2014)... With 3943.8% growth, Connexion Point ranks number 86 ... growing companies. The Inc. 500 ranks Connexion Point 12th, nationally, ... is the #1 fastest growing company in Utah. , Connexion ... its clients include four of the top 10 health care ... has offices and contact centers in Salt Lake City, Provo, ...
(Date:8/20/2014)... In contrast to evidence that the amygdala stimulates ... Primate Research Center, Emory University have found that ... hormones during the early development of nonhuman primates. ... Journal of Neuroscience . , The amygdala ... be important for responses to threatening situations and ...
(Date:8/20/2014)... New research reveals that, long ago, sea mammals may ... the infectious disease known as tuberculosis. Ancient strains ... and sea lions, who then spread it to people ... an international team of researchers. "Tuberculosis is a ... study and further research will help us understand how ...
Breaking Medicine News(10 mins):Health News:Study Ties Colds, Flu to Rare Risk of Stroke in Kids 2Health News:Study Ties Colds, Flu to Rare Risk of Stroke in Kids 3Health News:Perkins Eastman Expands Presence in China 2Health News:Perkins Eastman Expands Presence in China 3Health News:With 3943.8% Growth, Connexion Point, a Leader in Contact Centers for Health Care, Ranks 86th on the Inc. 500 List as One of the Nation’s Fastest Growing Companies 2Health News:Maturing brain flips function of amygdala in regulating stress hormones 2Health News:Maturing brain flips function of amygdala in regulating stress hormones 3Health News:Seals, Sea Lions Helped Global Spread of TB, Study Finds 2
... 12 /Xinhua-PRNewswire-FirstCall/ -- China,Medicine Corporation ("CMC") ... of prescription and over the counter ... made of Chinese herbs),Chinese herbs, nutritional ... formulations today announced the Company,s ADTZ,(Aflatoxin-detoxifizyme) ...
... reveal more damage compared to sporadic cases , FRIDAY, Oct. ... appears to cause more severe brain damage than the non-familial ... scans to examine the brains of 759 MS patients and ... more destructed lesions, and significantly lower volume of whole brain, ...
... for lowering cholesterol and maybe even fighting dementia, and ... slow decline in lung function in the elderly even ... it may be statins anti-inflammatory and antioxidant properties that ... in the second issue for October in the American ...
... WESTFIELD, N.J., Oct. 12 Don,t hire an ad agency; ... great marketing,ideas. It is not because an agency can,t come ... options to uncover new marketing ideas. Most clients follow ... out an RFP, interview agencies, then develop a,short list of ...
... CHICAGO, Oct. 11 Continuing its efforts ... SAVE THE PATIENT, a,not-for-profit patient-focused organization, is hosting ... Network. "Community Health Hotline" will,air Monday, October 15, ... Monday,s program will feature a frank discussion on ...
... 11 /Xinhua-PRNewswire/ -- On,October 10, 2007, Synutra International, ... of dairy-based nutritional products,for infants, children and adults, ... that the Company,s common stock is no longer ... on October 5, 2007 of the,Company,s quarterly report ...
Cached Medicine News:Health News:China Medicine's ADTZ Project Has Been Selected as One of Six Patent Commercialization Projects in Guangdong Province 2Health News:Familial MS May Be More Destructive 2Health News:Statins reduce loss of function, keeping old lungs young - even in smokers 2Health News:A New Way to Discover Marketing Ideas 2Health News:Patient Empowerment -- Medication Error 2Health News:Nasdaq Informs Synutra that the Company's Filing Delinquency has been Cured 2
Inquire...
Inquire...
Contour I pouches are light as a feather and feature our tapered SoftFlex skin barrier for comformability, flexbility and comfort. All Contour I pouches have ComfortWear panels that keep skin cool an...
Inquire...
Medicine Products: